Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

BPC-157 Dosing Protocol: 5 mg Vial — Daily Dosing Schedule & Supplies

Body Protection Compound-157 complete dosing guide for the 5 mg vial — subcutaneous, intramuscular, and oral protocols for tissue repair.

Go to peptide profileCalculate your dose

Quickstart highlights

BPC-157 (Body Protection Compound, GEPPPGKPADDAGLV) is a synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice.

  • Concentration: 2 mg/mL (5 mg vial + 2.5 mL bacteriostatic water).
  • At 2 mg/mL: 250 µg = 12.5 units, 500 µg = 25 units on a U-100 syringe.
  • Inject subcutaneously near the injury site for musculoskeletal repair; inject abdominally for systemic or gut protocols.
  • One 5 mg vial provides 10 daily doses at 500 µg or 20 doses at 250 µg.
  • Oral administration is viable — BPC-157 survives gastric acid due to its unique stability.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-425012.5Once daily250 µg — 12.5 units; conservative start near injury site (SC) or systemically
5-1250025Once daily500 µg — 25 units; standard therapeutic dose; one 5 mg vial provides 10 doses at this level

Gradual approach

WeekDose (µg)UnitsNotes
1-1220010200 µg once daily — ultra-conservative; suitable for gut healing or systemic anti-inflammatory protocols

Reconstitution steps

  1. Draw 2.5 mL bacteriostatic water; inject slowly down the vial wall.
  2. Swirl gently until the lyophilized powder dissolves; do not shake.
  3. Final concentration: 2 mg/mL (2,000 µg/mL). At 2 mg/mL: 250 µg = 12.5 units, 500 µg = 25 units on a U-100 syringe.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

4-week plan

  • 1 vial
  • 28 syringes
  • 3 mL bac water
  • 28 alcohol swabs

8-week plan

  • 2 vials
  • 56 syringes
  • 5 mL bac water
  • 56 alcohol swabs

12-week plan

  • 3 vials
  • 84 syringes
  • 8 mL bac water
  • 84 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Accelerate musculoskeletal tissue repair, reduce inflammation, and support gut mucosal healing through daily BPC-157 injections near the target tissue, harnessing its multi-pathway angiogenic and cytoprotective effects.

Cycle length: 12 weeks on.

Off-cycle: 4 weeks off after each 12-week cycle.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. Oral BPC-157 (if used): swallow immediately after drawing — do not refrigerate mixed oral solution.

Injection & tracking tips

  • For musculoskeletal injuries: inject subcutaneously near (not into) the injured tissue, typically within 2–5 cm of the site.
  • For systemic or gut-healing protocols: inject in the abdomen (standard SC site) or administer orally.
  • Oral BPC-157: draw the dose from the vial into a syringe, squirt into 2 oz water, swallow on an empty stomach. The peptide survives gastric acid due to its unique stability.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Rate injury pain on a 0–10 visual analogue scale (VAS) daily for the first 4 weeks.
  • Track range of motion for joint injuries every 2 weeks.
  • For gut protocols: record Bristol Stool Form Scale and bloating severity daily.
Log your cycle in the calculator →

How this works & references

BPC-157 (Body Protection Compound, GEPPPGKPADDAGLV) is a synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. Its tissue repair mechanisms include: (1) VEGFR2 activation and nitric oxide (NO) production driving angiogenesis at injury sites; (2) focal adhesion kinase (FAK-paxillin) pathway activation promoting fibroblast migration; (3) inhibition of inflammatory NF-κB signaling; (4) preservation of ALDH3 enzyme in rat tendon injury models. Šebečić et al. (1999) demonstrated accelerated Achilles tendon healing; Sikiric et al. (2011) documented duodenal ulcer healing. No completed human RCTs exist as of 2026; all evidence is preclinical.

Sources

  • Source: Šebečić B et al. — Osteogenic effect of BPC-157 on bone defect. J Orthop Res. 1999
  • Source: Sikiric P et al. — Novel cytoprotective medicament: BPC-157. Curr Pharm Des. 2011

Frequently asked questions

Where should I inject BPC-157 for a tendon or muscle injury?
Inject subcutaneously within 2–5 cm of the injured tissue — not directly into the tendon or muscle belly. For example, for an Achilles tendon injury, inject into the subcutaneous fat on the medial aspect of the lower calf, close to the tendon. This allows local VEGF-mediated angiogenesis and FAK pathway activation at the repair site.
Can I take BPC-157 orally instead of injecting?
Yes — BPC-157 is uniquely stable to gastric acid degradation, unlike most peptides. Oral administration at 250–500 µg daily on an empty stomach provides systemic and gut-local effects. Efficacy for peripheral musculoskeletal injuries may be lower than local injection; systemic anti-inflammatory and gut-healing effects are comparable.
How quickly should I expect results for a sports injury?
In rat Achilles tendon and bone defect models, measurable structural improvements appear within 1–3 weeks of daily BPC-157 injection. Human anecdotal reports suggest pain reduction within 1–2 weeks and improved range of motion within 4–6 weeks. Complete healing of chronic injuries may require 8–12 weeks.
Is it safe to combine BPC-157 with TB-500?
Yes — BPC-157 and TB-500 (Thymosin Beta-4 fragment) act through complementary mechanisms: BPC-157 drives angiogenesis via VEGFR2/NO and FAK pathways, while TB-500 promotes actin polymerization, stem cell recruitment, and anti-inflammatory signaling. The combination is widely used in injury repair protocols and is considered synergistic.
Does BPC-157 have any human clinical trial data?
As of 2026, no completed Phase 2 or Phase 3 human clinical trials for BPC-157 have been published. All published efficacy data comes from animal models (rats, mice). Human use is based on extrapolation from preclinical data and anecdotal reports. This limits evidence quality to 'very low' per GRADE classification.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →